Q4 2026 Fortis Healthcare Ltd Earnings Call Transcript
Key Points
- Fortis Healthcare Ltd (BOM:532843) reported a consolidated revenue growth of 17.3% for FY26, reaching INR9,128 crores.
- The hospital business revenue grew by 19.1% to INR7,773 crores, contributing significantly to the overall revenue.
- Operating EBITDA margins for the hospital business improved from 20.5% in FY25 to 22.2% in FY26.
- The company added approximately 800 beds through brownfield expansion and acquisitions, enhancing its capacity.
- Revenue from international patients grew by 18.5%, contributing 7.8% to the overall hospital business revenue.
- Occupancy rates in some larger hospitals, such as FMRI and BG Road, have dropped, partly due to a decline in international business.
- The net debt increased to INR2,334 crores, with a net debt-to-EBITDA ratio rising to 1.09x due to acquisitions and investments.
- The diagnostic business saw a decline in operating EBITDA margin in Q4 FY26, dropping to 20.1% from 23.4% in Q4 FY25.
- The company faces challenges from capped drug prices in the CGHS and ECHS segments, impacting revenue and occupancy.
- Intense competition in certain regions, such as Bangalore, affects occupancy levels and revenue growth potential.
Ladies and gentlemen, good day, and welcome to Fortis Healthcare Limited Q4 FY26 earnings conference call. Please note that this conference is being recorded. I now hand the conference over to Mr. Anurag Kalra, Head of Investor Relations. Thank you, and over to you, Mr. Kalra.
Thank you, Renju. A very good morning and good afternoon, ladies and gentlemen, and thank you indeed for taking the time to join us on our quarter four FY26 and FY26 earnings call. The call is being chaired by our MD and CEO, Dr. Ashutosh Raghuvanshi. With him, we have our Chief Financial Officer, Mr. Vivek Goyal.
From Agilus, we have the CEO, Mr. Anand; and the CFO, Mr. Akshay Tiwari. We will start the call with some opening remarks on the performance by Dr. Raghuvanshi, post which Anand will take you through certain key highlights of the Diagnostics business, and then we can open the floor for question and answers.
Over to Dr. Raghuvanshi.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
